Advertisement


Thomas J. Smith, MD, on Oral Abstract Session B (2017 Quality Care Symposium)

2017 Quality Care Symposium

Advertisement

Thomas J. Smith, MD, of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, summarizes two papers for which he was a discussant: reducing overuse of colony-stimulating factors without compromising the safety of patients with lung cancer receiving chemotherapy, and a cost-and-survival analysis before and after implementing Dana-Farber Clinical Pathways for patients with stage IV non–small cell lung cancer (Abstracts 3, 52).



Related Videos

Cost of Care
Symptom Management

Laura E. Panattoni, PhD, on Costs of Preventable Emergency Department Use

Laura E. Panattoni, PhD, of the Fred Hutchinson Cancer Research Center, discusses results from a regional study on emergency department costs during cancer treatment and the need to focus on managing symptoms (Abstract 2).

Issues in Oncology

John V. Cox, DO, MBA, on 2017 Quality Care Symposium Highlights: Expert Perspective

John V. Cox, DO, MBA, of the Parkland Health System/UTSW, discusses some of the key presentations at the 2017 Quality Care Symposium (Abstracts 3, 37, 52).

Issues in Oncology

Greg D. Judy, MD, on Safety Incidents in Radiotherapy

Greg D. Judy, MD, of UNC Health Care, discusses the contributing factors, and possible fixes, for near-miss and actual safety incidents in patients being treated with radiotherapy.

Symptom Management

Ethan M. Basch, MD, on Symptom Control and Quality: The Patient’s Voice

Ethan M. Basch, MD, of The University of North Carolina at Chapel Hill, discusses programs—now rolling out at various institutions—that use direct patient reporting of symptoms as a part of quality assessment (Posters 61, 81; Abstract 218).

Issues in Oncology

Brian Weiss, MD, on Reducing Treatment Errors With Improvement Science

Brian Weiss, MD, of Cincinnati Children’s Hospital Medical Center, discusses a program designed to eliminate errors in chemotherapy use among pediatric patients whose regimens incorporate multiple drugs and rigorous monitoring schedules (Abstract 37).

Advertisement

Advertisement




Advertisement